Kenneth Custer: key facts
- Kind of voice
- Sector leader
- Role
- President of Lilly's cardiometabolic health unit
- Quoted on
- Diabetes
- Press citations held
- 2
- Most recently quoted
- 29 Sept 2026
“Delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes. Onswik offers a new once-weekly basal insulin option for patients and reflects our continued commitment to deliver innovative treatment options that expand choice and provide greater flexibility in how people manage type 2 diabetes.”
What Kenneth Custer has said
“For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes.”
Ph.D., EVP and president of cardiometabolic health at Eli Lilly · Diabetes · 29 Sept 2026 · Lilly brings more heat to Novo with FDA nod for once-weekly insulin Onswik ↗
Where Kenneth Custer has been quoted
- Lilly's rival to Novo's new Awiqli insulin gets FDA approvalpharmaphorum.com · 29 Sept 2026
- Lilly brings more heat to Novo with FDA nod for once-weekly insulin Onswikfiercepharma.com · 29 Sept 2026
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 29 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.